Methods for treating neurodegenerative disorders
Inventors
Kocis, Petr • TOLAR, Martin • Hey, John
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-12036208-B2
Publication Date
2024-07-16
Expiration Date
Abstract
Methods of treating a disease characterized by amyloid aggregates are provided herein.
Core Innovation
The invention relates to methods of treating diseases characterized by amyloid aggregates, including Alzheimer’s disease and related amyloid disorders. The methods comprise administering compounds having defined core structures, where the compounds are described by structural formulas I–IV and are also provided as pharmaceutically acceptable salts.
The compounds include structural features defined by variable ring systems and functional groups, including sulfonic acid/sulfonate-like moieties. The disclosure specifies permissible substituent and variable ranges and further narrows preferred embodiments, including quaternary-nitrogen bicyclic variants and multiple compound embodiments identified within the structural formulas.
The disclosure further recites pharmaceutical composition use in connection with the administering methods. It includes a pharmaceutically acceptable carrier, a unit dosage form, and oral administration as an administration route.
Claims Coverage
The claim coverage includes one independent claim directed to treating Alzheimer’s disease by administering a selected compound or a pharmaceutically acceptable salt. A dependent claim further specifies formulation into a pharmaceutically acceptable composition including a pharmaceutically acceptable carrier. The coverage centers on administration of a structurally defined compound set.
Treating Alzheimer's disease by administering a selected compound
A method of treating Alzheimer's disease comprising administering to a subject in need thereof a compound selected from the specified set or a pharmaceutically acceptable salt of any of the foregoing.
Formulating the selected compound with a pharmaceutically acceptable carrier
The method further includes formulating the selected compound into a pharmaceutically acceptable composition that includes a pharmaceutically acceptable carrier.
The claims coverage is centered on administering a selected compound or pharmaceutically acceptable salt for treating Alzheimer’s disease, with a dependent refinement to formulate the compound in a pharmaceutically acceptable composition including a pharmaceutically acceptable carrier.
Stated Advantages
Provides treatment of amyloid aggregate, including Alzheimer’s disease, using the disclosed compounds.
Documented Applications
Treatment of diseases characterized by amyloid aggregates, with Alzheimer's disease identified as a primary example.
Treating Alzheimer's disease by administering compounds having defined core structures (structural formulas I–IV) or pharmaceutically acceptable salts.
Interested in licensing this patent?